Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from NeOnc Technologies Holdings, Inc. ( (NTHI) ).
On November 12, 2025, NeOnc Technologies Holdings, Inc. announced updated clinical results from its Phase 1/2a and compassionate care studies involving 24 patients with recurrent Grade III/IV IDH1-mutant astrocytoma treated with NEO100. The results showed significant radiographic response in 21% of patients and a 44% six-month progression-free survival rate, surpassing historical benchmarks. Additionally, 33% of patients demonstrated long-term survival of 18 months or more, with no significant toxicity reported. These findings suggest NEO100 could represent a paradigm shift in treating recurrent IDH1-mutant gliomas, potentially offering a new standard of care.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on developing and commercializing central nervous system therapeutics designed to overcome the blood-brain barrier. The company has a portfolio of novel drug candidates, including NEO100 and NEO212, which are in Phase II clinical trials and have received FDA Fast-Track and IND status. NeOnc has licensed an extensive patent portfolio from the University of Southern California for oncological and neurological applications.
Average Trading Volume: 78,604
Technical Sentiment Signal: Strong Buy
Current Market Cap: $194.3M
Find detailed analytics on NTHI stock on TipRanks’ Stock Analysis page.